|
TNFRSF11A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we used ovariectomy in female mice to show that RANK deletion in NPY neurones attenuates bone loss caused by long-term oestrogen deficiency, particularly in the vertebral compartment.
|
30633834 |
2019 |
|
TNFRSF11A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hexane Fraction of <i>Turbo brunneus</i> Inhibits Intermediates of RANK-RANKL Signaling Pathway and Prevent Ovariectomy Induced Bone Loss.
|
31555218 |
2019 |
|
TNFRSF11A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces ovariectomy-induced bone loss in mice.
|
29348072 |
2018 |
|
TNFRSF11A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that MLB can suppress LPS-induced bone loss via inhibiting RANKL/RANK related osteoclast formation.
|
29472860 |
2018 |
|
TNFRSF11A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human neutrophils express the osteoclast activation factor RANKL (receptor activator of NF-kB ligand) and act directly on osteoclasts to promote bone loss.
|
27552066 |
2017 |
|
TNFRSF11A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, DMY prevented bone loss and decreased serum levels of tumor necrosis factor-α, interleukin-1β, and interleukin-6, and with a decrease in the ratio between receptor activator of nuclear factor-κB (RANK) ligand (RANKL) and osteoprotegerin (OPG) <i>in vivo</i>.
|
29311931 |
2017 |
|
TNFRSF11A
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will summarize our current knowledge of the role of the OPG/RANK-RANKL pathway in B cells in health and disease, and the contribution of B cells to HIV-induced bone loss.
|
29312334 |
2017 |
|
TNFRSF11A
|
0.100 |
Biomarker
|
disease |
BEFREE |
RANKL/RANK: from bone loss to the prevention of breast cancer.
|
27881737 |
2016 |
|
TNFRSF11A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The RANK gene might contribute to genetic variability in L1-L4 BMD in postmenopausal Chinese women with osteoporosis or osteopenia.
|
26426211 |
2016 |
|
TNFRSF11A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
10 μg of RANK siRNA exerted a protective effect against PE particle-induced osteolysis, decreasing the bone loss and the osteoclastogenesis, demonstrated by the significant increase in the bone volume (P<0.001) and by the reduction in both the number of TRAP(+) cells and osteoclast activity (P<0.01).
|
25462844 |
2015 |
|
TNFRSF11A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vivo, silencing of miR-503 using a specific antagomir in ovariectomy (OVX) mice increased RANK protein expression, promoted bone resorption, and decreased bone mass, whereas overexpression of miR-503 with agomir inhibited bone resorption and prevented bone loss in OVX mice.
|
23821519 |
2014 |
|
TNFRSF11A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
|
23303667 |
2013 |